MLH3-Targeting Oligonucleotides for Trinucleotide Repeat Suppression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Trinucleotide repeat expansion disorders, such as Huntington's disease and fragile X syndrome, are caused by genetic mutations leading to defective or toxic gene products, impairing RNA transcription and causing progressive nerve cell degeneration, with existing treatments lacking effective methods to inhibit the expression of genes associated with these disorders.

Innovation Solution

The use of single-stranded oligonucleotides, 10-30 nucleosides in length, with specific regions complementary to the MLH3 gene, to inhibit its expression by degrading MLH3 mRNA transcripts, thereby reducing the progression of trinucleotide repeat expansion disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If single-stranded oligonucleotides are used to inhibit MLH3 gene expression, then the progression of trinucleotide repeat expansion disorders is reduced, but the complexity of the treatment method increases

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidcomplexity of treatment method

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs single-stranded oligonucleotides as intermediary molecules that specifically bind to MLH3 mRNA transcripts through complementary base pairing. These oligonucleotides act as mediators between the therapeutic goal (inhibiting MLH3 expression) and the molecular target (mRNA), forming stable hybridization complexes that recruit RNase H for selective degradation of the target RNA without affecting other cellular components

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces traditional mechanical or surgical intervention approaches with a molecular-level biochemical mechanism. Instead of physical manipulation of cells or tissues, the treatment utilizes specific molecular recognition and biochemical degradation pathways (RNase H-mediated RNA cleavage) to achieve therapeutic effects, thereby reducing procedural complexity while maintaining reliability

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Productivity

If oligonucleotides are designed with high complementarity to MLH3 gene, then mRNA inhibition efficiency is increased, but the risk of off-target effects increases

Engineering Contradiction:

ImprovemRNA inhibition efficiencyVSAvoidoff-target effects

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by designing oligonucleotides with varying degrees of complementarity at different regions. The core binding region has high complementarity (at least 80%, preferably 90-95%) to ensure strong and specific binding to the target MLH3 mRNA, while flanking regions may have reduced complementarity or contain intentional mismatches to enhance specificity and reduce off-target binding, creating a gradient of binding affinity along the oligonucleotide sequence

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent systematically varies key parameters of the oligonucleotide design including length (10-30 nucleotides), complementarity percentage (80%-95%), and sequence composition to optimize the balance between binding efficiency and specificity. By adjusting these parameters, the treatment achieves high mRNA inhibition while minimizing cross-reactivity with non-target sequences through precise control of thermodynamic and kinetic properties

Inventive Principle:

Principle #35Parameter changes

3Ease of operation

If short oligonucleotides (10-30 nucleosides) are used, then cellular uptake and delivery are improved, but the stability of the oligonucleotides decreases

Engineering Contradiction:

Improvecellular uptake and deliveryVSAvoidstability of oligonucleotides

Core Design Contradiction:

Ease of operationVSDuration of action of stationary object

Solution Approach 1:

The patent employs composite oligonucleotide structures combining different nucleoside types and modifications. The oligonucleotides contain a mix of standard and modified nucleosides (including 2′-O-methoxyethyl, locked nucleic acid, or other sugar modifications) that create a composite material with optimized properties: the modified nucleosides enhance nuclease resistance and thermal stability while maintaining or improving cellular uptake efficiency compared to unmodified sequences of the same length

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The oligonucleotides effectively inhibit MLH3 gene expression, reducing trinucleotide repeat expansions and potentially slowing the progression of associated diseases by degrading MLH3 mRNA, demonstrating significant mRNA inhibition in cell assays.

Implementation Method 1

the oligonucleotide comprises a region of at least 10 contiguous nucleobases having at least 80% complementarity to an MLH3 gene

Methodology Applied

Scientific EffectComplementary base pairing:

Implementation Method 2

inhibiting expression of a human MLH3 gene in a cell by degrading MLH3 mRNA transcripts

Methodology Applied

Scientific EffectRNase H-mediated degradation:

Data Source

PatentUS12485136B2Methods for the treatment of trinucleotide repeat expansion disorders associated with MLH3 activity

Publication Date: 2025.12.02 TAKEDA PHARMACEUTICALS USA INC

AI summary

The present disclosure features useful compositions and methods to treat repeat expansion disorders, e.g., in a subject in need thereof. In some aspects, the compositions and methods described herein are useful in the treatment of disorders associated with MLH3 activity.